Drugs in development for the treatment of schizophrenia. - Test2 - elhamkhani - TriplyDB

Drugs in development for the treatment of schizophrenia.

Drugs in development for the treatment of schizophrenia.

http://www.wikidata.org/entity/Q37546125

about

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats.Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats 5-HT2A Serotonin Receptor Density in Adult Male Rats' Hippocampus after Morphine-based Conditioned Place Preference Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.Risperidone improves interpersonal perception and executive function in patients with schizophrenia.Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods.

P2860

Q34274859-235D4E3C-5064-4CF2-B4D2-23A81F69B503 Q36846918-5B4AA562-5002-4F0F-BA86-70F40F0D6C75 Q37111054-C3FCBDB6-5FF5-4E90-951D-A3D72E3C72F4 Q37168939-9825561B-F273-422C-8FF3-A4BA95250BA9 Q37862242-6B06598A-D94C-4F26-A726-6CD89E9726B8 Q40571141-F9BAD5D9-C2C7-4753-A14D-3ECB808B6353 Q48234174-AE16B6EA-D560-489A-BF0A-3C6E17CC0829 Q54308890-2E4703AE-2C94-4BA3-BD67-96C641BE9A29

P2860

Drugs in development for the treatment of schizophrenia.

http://www.wikidata.org/entity/Q37546125

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drugs in development for the treatment of schizophrenia.

@en

Drugs in development for the treatment of schizophrenia.

@nl

type

label

Drugs in development for the treatment of schizophrenia.

@en

Drugs in development for the treatment of schizophrenia.

@nl

prefLabel

Drugs in development for the treatment of schizophrenia.

@en

Drugs in development for the treatment of schizophrenia.

@nl

P1433

Q37546125-DFBEBD49-96BD-4B10-895D-137CABF03DDE

P1476

Q37546125-58428EBF-770F-401D-979B-D97C5A2DE800

P2093

Q37546125-9835ED5E-F380-445A-A4AE-76B3E8310B43

P2860

Q37546125-021C5646-890A-48CA-A898-7B33075F9F08

Q37546125-0A62203D-BA66-4539-AD11-A2A80A64E593

Q37546125-110E4375-95B4-4951-ABE7-50909BEE0008

Q37546125-195468ED-2566-4402-A573-600DC699E379

Q37546125-19A356F6-48E0-45A1-854F-90AC4E1596C7

Q37546125-239F0F62-7FF7-4DFF-A939-A14B5E8AD8A8

Q37546125-2438A9BC-8D56-4008-9627-5B0A100AFF68

Q37546125-25E48E82-9D4A-4DEE-BDB7-DD5C53ED65F2

Q37546125-2BBDDE5F-6992-4146-A16E-902B9B310D57

Q37546125-30273D98-E89D-4888-B7C0-515CC2F34DCA

P304

Q37546125-39822030-3AAC-475A-BEC2-FCAFE377F00D

P31

Q37546125-E8B8CA03-261D-4618-8632-51A053E45BE5

P356

Q37546125-5287DB0C-98E5-46CC-80D0-28738DC49D2C

P407

Q37546125-4442F691-3F20-43E5-BCD7-2343B2884DA0

P433

Q37546125-2677271D-AEEB-48A4-9E9F-5129104C502E

P478

Q37546125-40FA790E-3B2B-4161-BC86-87CF617B201F

P577

Q37546125-10AE3BB0-2727-422A-A1C4-3AFD274D459A

P698

Q37546125-20AD814A-A1BD-4977-A9DD-C2F7BFD1476D

P921

Q37546125-129C10E3-F537-441B-A937-275025398CCE

P356

13543780903066756

P1433

Expert Opinion on Investigational Drugs

P1476

Drugs in development for the treatment of schizophrenia.

@en

P2093

Robin Emsley

http://www.w3.org/2001/XMLSchema#string

P2860

Refractory schizophrenia and atypical antipsychotics

Genes for schizophrenia? Recent findings and their pathophysiological implications

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

The evolution of drug development in schizophrenia: past issues and future opportunities.

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Size of burden of schizophrenia and psychotic disorders.

P304

1103-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780903066756

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19589093

http://www.w3.org/2001/XMLSchema#string

P921